Shanghai, January 6, 2022 – BioDuro-Sundia won the “Best Partner Award in Chemistry & Biology 2021” issued by Haihe Biopharma Drug Discovery Department, in recognition of the great contribution by our drug discovery team in 2021. Dr. Bing Yu, Senior Director of Drug Discovery Biology, and Dr. Wangyang Tu, Senior Director of Medicinal Chemistry, visited our Zhangjiang R&D Center, and shared the joy together with the Drug R&D team of BioDuro-Sundia. Dr. Jiong Chen, Vice President of Shanghai Zhangjiang Chemistry R&D Department, Dr. Teng Lin, Senior Director of Drug Discovery Biology and Mr. Zhenhan Lei, Senior Commercial Director, received the award and presented the project summary.

Dr. Wangyang Tu highly praised the BioDuro-Sundia chemistry team, “Our partnership has been greatly enhanced in 2021. Comparing to other CRO companies, BioDuro-Sundia has done a fantastic job with their solid experience, high efficiency and timely feedback- which are three important factors we valued. “Dr. Jiong Chen expressed his gratitude, and attributed this honor to the hard work of every member of the team. “It is our honor to be recognized by Haihe, and we will continue to maintain high efficiency and high quality throughout our partnership. In the future, our team will expand comprehensively to provide even better services for Haihe as well as maintaining a long-term and stable relationship.”

After Dr. Lin Teng’s introduction and future plans for the department, Dr. Bing Yu expressed his good expectations for BioDuro-Sundia, “The overall industry is continuing its vigorous growth. It is happy to see that BioDuro-Sundia keeps its pace of development and obtained further competitiveness. I feel very confident in our future partnership.” Dr. Lin Teng also expressed his thankfulness to Haihe, “Dr. Bing Yu provided constructive feedback and support to our team during our cooperation. We will continue to improve the overall strength of the team and hope to have a long lasting and continuous partnership with Haihe. And we all wish Haihe continued development and growth.”

Zhenhan Lei, Senior Business Director, finally expressed his heartfelt thanks to Haihe Biopharma for awarding our team, said: ” BioDuro-Sundia will continue to cooperate in a more comprehensive capabilities in the future, with rapid experimental data feedback, and better service quality as a reward for customers’ trust in us!

By January 2022, BioDuro-Sundia’s drug discovery team has expanded to 1700+ employees, covering chemistry, biology, pharmacology, biological and pharmacokinetics services sectors.  With R&D centers in Shanghai, Beijing, Wuxi, Taipei and San Diego, USA, we can provide a full range of one-stop drug discovery support for both individual and integrated projects.

About Haihe Biopharma

Haihe Biopharma is a leading innovation-driven biotechnology company in China. Focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. As a new drug R&D company led by an academician of the Chinese Academy of Engineering, Haihe Biopharma is committed to the path of independent innovation. It also has a research and management team with a global perspective, and it is proactively mapping out the international development of innovative drugs.

Currently, 7 of the 13 core products in the Haihe’s R&D pipeline have entered the clinical development stage, and 5 have obtained IND approval from the US FDA.

About BioDuro-Sundia

BioDuro-Sundia, an Advent International portfolio company, is a leading contract research, development and manufacturing organization (CRDMO) that provides biopharmaceutical partners with fully integrated services to support drug discovery, development and manufacturing for both drug substance and drug product-– from discovery to commercialization.  The company is the industry’s top largest, with major operations in China and the US—featuring more than 2,400 employees and 11 global sites.

Register Now!
Webinar: New Modality - Peptides Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform
June 19, 2024 at 10am ET / 07am PT / 04pm CET
View more
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all